- Home
- KROS vs IRMD Comparison
KROS vs IRMD Comparison
Compare KROS & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- IRMD
- Stock Information
- Founded
- KROS 2015
- IRMD 1992
- Country
- KROS United States
- IRMD United States
- Employees
- KROS N/A
- IRMD N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- IRMD Medical/Dental Instruments
- Sector
- KROS Health Care
- IRMD Health Care
- Exchange
- KROS Nasdaq
- IRMD Nasdaq
- Market Cap
- KROS 558.9M
- IRMD 756.5M
- IPO Year
- KROS 2020
- IRMD 2014
- Fundamental
- Price
- KROS $13.45
- IRMD $61.80
- Analyst Decision
- KROS Buy
- IRMD Strong Buy
- Analyst Count
- KROS 13
- IRMD 1
- Target Price
- KROS $20.63
- IRMD $72.00
- AVG Volume (30 Days)
- KROS 603.2K
- IRMD 64.4K
- Earning Date
- KROS 08-06-2025
- IRMD 07-31-2025
- Dividend Yield
- KROS N/A
- IRMD 1.10%
- EPS Growth
- KROS N/A
- IRMD 10.72
- EPS
- KROS 0.11
- IRMD 1.55
- Revenue
- KROS $214,713,000.00
- IRMD $75,154,639.00
- Revenue This Year
- KROS $5,006.76
- IRMD $10.62
- Revenue Next Year
- KROS N/A
- IRMD $9.69
- P/E Ratio
- KROS $123.44
- IRMD $39.88
- Revenue Growth
- KROS 91657.70
- IRMD 11.04
- 52 Week Low
- KROS $9.12
- IRMD $42.34
- 52 Week High
- KROS $72.37
- IRMD $63.29
- Technical
- Relative Strength Index (RSI)
- KROS 45.45
- IRMD 65.96
- Support Level
- KROS $13.24
- IRMD $59.50
- Resistance Level
- KROS $13.77
- IRMD $60.94
- Average True Range (ATR)
- KROS 0.37
- IRMD 1.60
- MACD
- KROS -0.04
- IRMD 0.00
- Stochastic Oscillator
- KROS 38.67
- IRMD 90.53
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.